

# Biosynthetic pathway for a new series of gangliosides, GT1a $\alpha$ and GQ1b $\alpha$

Fumitoshi Irie<sup>a,b</sup>, Kazuya I.-P. Jwa Hidari<sup>b</sup>, Tadashi Tai<sup>c</sup>, Yu-Teh Li<sup>b,d</sup>, Yousuke Seyama<sup>a</sup>,  
Yoshio Hirabayashi<sup>b,\*</sup>

<sup>a</sup>Department of Physiological Chemistry and Nutrition, Faculty of Medicine, The University of Tokyo, Hongo, Bunkyo-ku, Tokyo 113, Japan

<sup>b</sup>Laboratory for Glyco Cell Biology, Frontier Research Program, The Institute of Physical and Chemical Research (RIKEN), Hirosawa, Wako-shi, Saitama 351-01, Japan

<sup>c</sup>Department of Tumor Immunology, The Tokyo Metropolitan Institute of Medical Science, Hon-komagome, Bunkyo-ku, Tokyo 113, Japan

<sup>d</sup>Department of Biochemistry, Tulane University School of Medicine, New Orleans, LA 70112-2699, USA

Received 18 July 1994; revised version received 24 July 1994

**Abstract** A new class of gangliosides, GT1a $\alpha$  and GQ1b $\alpha$ , were initially identified as cholinergic neuron-specific antigens in bovine brain. These gangliosides have in common  $\alpha$ 2-6 NeuAc linked to the GalNAc residue in the gangliotetraose core structure. In this study, we have determined the biosynthetic pathways of GT1a $\alpha$  and GQ1b $\alpha$  using rat liver Golgi fraction. The results showed that GT1a $\alpha$  and GQ1b $\alpha$  were synthesized from GD1a and GT1b, respectively, by the action of a GalNAc  $\alpha$ 2-6 sialyltransferase. It was also demonstrated that these two gangliosides were found to exist as extremely minor components in rat liver.

**Key words:** Ganglioside; Sialyltransferase; Ganglioside biosynthesis; Cholinergic neuron-specific antigen

## 1. Introduction

Gangliosides, sialic acid-containing glycosphingolipids, have been shown to be involved in a variety of biological phenomena, such as cell–cell interactions, growth, differentiation, cell transformation, and signal transduction pathways [1–4]. We have found that bovine brain contained more than 100 species of gangliosides including extremely minor components [5]. In fact, we have isolated and characterized several new species of gangliosides such as  $\alpha$ -series gangliosides [6], de-*N*-acetylated GM1 [7], hybrid type gangliosides containing GM2 epitope [8], and cholinergic neuron-specific gangliosides [9,10].

The occurrence of cholinergic neuron-specific gangliosides (Chol-1) was first described by Richardson et al. using a polyclonal antibody (anti-Chol-1) against synaptic plasma membrane of electric organ from *Torpedo marmorata* [11]. Immunohistochemical staining with polyclonal and monoclonal antibody (GGR-41) revealed that the antigens were characteristically distributed on the cell bodies and nerve terminals of the cholinergic neurons in the central and peripheral neurons [12,13]. Although Chol-1 gangliosides were expected to be functionally important molecules in the cholinergic system, their chemical structures have not been identified because they are extremely minor components. Recently, we have determined the chemical structures of two novel Chol-1 gangliosides as GT1a $\alpha$  and GQ1b $\alpha$  [9,10]. It is of interest to note that both gangliosides contained NeuAc attached to GalNAc through an  $\alpha$ 2-6 linkage (Fig. 1).

We have attempted to study the sialyltransferase activities responsible for the synthesis of Chol-1 gangliosides in micro-

somal fraction prepared from rat brain. However, the enzymatic activity was too low to be detected. Subsequently we found that rat liver Golgi fraction contained sialyltransferase activity capable of synthesizing Chol-1 gangliosides. This communication describes the pathway for the biosynthesis of unique gangliosides, GT1a $\alpha$  and GQ1b $\alpha$ , using a Golgi fraction prepared from rat liver. The natural occurrence of these two gangliosides in rat liver is also described.

## 2. Materials and methods

### 2.1. Materials

Donryu rats (female, 4-week-old) were purchased from SLC Inc. (Hamamatsu, Japan). CMP-[<sup>14</sup>C]NeuAc (11.3 GBq/mmol) was obtained from NEN Research Products (Boston, USA). CMP-NeuAc was from Sigma Chemical Company (St. Louis, USA). Gangliosides from bovine brain were prepared as described previously [6,9,10]. GD1a $\alpha$  and GT1b $\alpha$  were prepared by the treatment of GT1a $\alpha$  and GQ1b $\alpha$ , respectively, with sialidase L which specifically hydrolyzes the NeuAc  $\alpha$ 2-3Gal linkage [14]. Sialidase L was isolated and purified as described [15]. Peroxidase-labeled goat anti-mouse IgG and IgM were purchased from Jackson ImmunoResearch Lab. (Avondale, PA). Mouse monoclonal antibody specific for cholinergic gangliosides, GT1a $\alpha$  and GQ1b $\alpha$ , was prepared as described in detail elsewhere [16]. All other chemicals were of highest purity available.

### 2.2. TLC

Analytical TLC was carried out on precoated HPTLC plates (Silica Gel 60, E. Merck) using the following solvent systems: chloroform/methanol/12 mM MgCl<sub>2</sub> (5:4:1, by volume; solvent A), chloroform/methanol/12 mM MgCl<sub>2</sub> (4:5:1, by volume; solvent B), and chloroform/methanol/12 mM MgCl<sub>2</sub>/15 M NH<sub>4</sub>OH (50:40:7:3, by volume; solvent C). Gangliosides were visualized with resorcinol/HCl reagent.

### 2.3. TLC-immunostaining

TLC-immunostaining was performed by the method of Kusunoki et al. [17]. Gangliosides were applied onto a plastic plate (Poligram Sil G, Nagel, Germany) and developed with a combination of solvent system A and C. The plate was subjected to immunostaining with a monoclonal antibody against GT1a $\alpha$  and GQ1b $\alpha$  (GGR-41, mouse IgG2a) [16]. Densitometric analysis was carried out by dual-wavelength densitometric scanner, Shimadzu CS-9000 (Shimadzu, Kyoto, Japan) for quantification of the gangliosides.

\*Corresponding author. Fax: (81) (48) 462 4690.

**Abbreviations:** The nomenclature used for gangliosides is based on the system of Svennerhorm and Hirabayashi et al. [9,24]. Cer, ceramide; Gal, galactose; Glc, glucose; GalNAc, *N*-acetylgalactosamine; NeuAc, *N*-acetylneuraminic acid; TLC, thin layer chromatography; HPTLC, high performance thin layer chromatography.

#### 2.4. Sialyltransferase assay using rat liver Golgi fraction and identification of the reaction products

Rat liver Golgi fraction was prepared by the method of Sandberg et al. [18]. Sialyltransferase activity was measured by the method of Hidari et al. [19] with a slight modification. In brief, the reaction mixture contained 15 nmol GD1a or GT1b, 3.2 mM CMP-[ $^{14}$ C]NeuAc (155 MBq/mmol), 0.4% Triton CF-54, 10 mM MnCl<sub>2</sub>, 10 mM MgCl<sub>2</sub>, 1 mM 2-mercaptoethanol, 150 mM Na cacodylate/HCl buffer (pH 6.5), and 50  $\mu$ g of Golgi protein in a total volume of 50  $\mu$ l. The mixture was incubated for 2 h at 37°C. The reaction was terminated by addition of 0.5 ml of water. The reaction products were desalted by ASPEK pak tC18 CARTRIDGE column chromatography (M&S Instruments Trading Inc., Tokyo, Japan). Subsequently, the products were dissolved in 200  $\mu$ l of methanol and applied onto a Sephadex LH-60 column (0.8  $\times$  5 cm) which had been equilibrated with methanol. Fractions of 50  $\mu$ l of the effluent were collected, and fraction number 14–17 containing the radioactive ganglioside products were pooled and analyzed by TLC and TLC-immunostaining. Amounts of reaction products were calculated by densitometric analysis with BAS 2000 (Fuji Film, Tokyo, Japan) based on the calibration curve of CMP-[ $^{14}$ C]NeuAc. For identification of their chemical structures, the reaction products were further purified by preparative TLC and analyzed by TLC-immunostaining with GGR-41.

#### 2.5. Preparation of ganglioside fraction from rat liver

Fresh rat tissues of brain and liver (4-week-old) were dissected and lyophilized. Ganglioside was obtained by sequential extraction with 10 vol. of chloroform/methanol (2:1, v/v) and chloroform/methanol/water (5:5:1, by volume). The extracts were combined, treated with 0.5 M KOH in methanol for 30 min at 37°C [20], dialyzed against water and lyophilized.

### 3. Results and discussion

#### 3.1. Presence of sialyltransferase activity capable of synthesizing GT1a $\alpha$ and GQ1b $\alpha$ in rat liver

In order to determine the biosynthetic pathways of Chol-1 gangliosides, several species of gangliosides were examined for their ability to serve as substrate for sialyltransferases in rat liver Golgi fraction. As shown in Table 1, among the gangliosides tested, only products derived from GD1a and GT1b reacted with monoclonal antibody GGR-41 against GT1a $\alpha$  and GQ1b $\alpha$ . Putative precursors such as GD1a $\alpha$  and GT1b $\alpha$ , which were isolated as another type of Chol-1 ganglioside (unpublished results), have no potency to serve as substrates for Gal  $\alpha$ -3 sialyltransferase.

To confirm the chemical structures of the synthesized products, they were characterized by TLC (Fig. 2) and TLC-immunostaining with GGR-41 which is specific for GT1a $\alpha$  and GQ1b $\alpha$  (Fig. 3). As shown in Fig. 2, the TLC mobilities of two major products synthesized from GD1a were identical to those of GT1a and GT1a $\alpha$ , respectively. Similarly, when GT1b was used, the two major products migrated to the positions identical to those of GQ1b and GQ1b $\alpha$ , respectively. Previously, Iber et al. reported that a single  $\alpha$ -2-8 sialyltransferase in rat liver synthesized GT1a and GQ1b from GD1a and GT1b, respectively [21]. In the present study, we identified two additional products, GT1a $\alpha$  and GQ1b $\alpha$ .

As expected, the gangliosides gave positive reaction with GGR-41, indicating that the products from GD1a and GT1b are GT1a $\alpha$  and GQ1b $\alpha$ , respectively (Fig. 3). The amounts of radiolabeled products, GT1a $\alpha$  and GQ1b $\alpha$ , were approximately 2.6 and 2.9 pmol, respectively, under our incubation conditions, and agreed with the amounts obtained from densitometric analysis of TLC-immunostaining.

For maximum enzyme activity, divalent metal ions, Mg<sup>2+</sup>




Fig. 1. Chemical structures of GT1a $\alpha$  and GQ1b $\alpha$ .

and Mn<sup>2+</sup> were shown not to be required (Table 2). Similar to other sialyltransferases for ganglioside biosynthesis, addition of the detergent Triton CF-54 was effective.

Recently, GD1 $\alpha$  synthase (GalNAc  $\alpha$ -2-6 sialyltransferase)

Table 1. Biosynthesis of GT1a $\alpha$  and GQ1b $\alpha$  in rat liver

	Acceptor	Immunoreactive product with GGR-41	Activity (pmol/mg protein/h)
GD1a		GT1a $\alpha$	26.0 <sup>a</sup> 25.7 <sup>b</sup>
GD1 $\alpha$		n.d.	n.d.
GD1a $\alpha$		n.d.	n.d.
GT1b		GQ1b $\alpha$	28.6 <sup>a</sup> 29.0 <sup>b</sup>
GT1b $\alpha$		n.d.	n.d.
GT1a $\alpha$		n.d.	n.d.

The sialyltransferase activities were measured by <sup>a</sup>BAS2000 and <sup>b</sup>TLC-immunostaining with GGR-41. n. d., Not detected.

● : Glc, ○ : Gal, ■ : GalNAc, △ : NeuAc, — : Cer




Fig. 2. Reaction products from GD1a or GT1b by rat liver sialyltransferase. Reaction products from GD1a and GT1b (panel II and IV, respectively) were analyzed with FUJIX BAS 2000. Standard gangliosides were visualized by resorcinol/HCl reagent (panel I and III). Lane 1 and lane 6, standard ganglioside mixture (GM3, GM2, GM1a, GD1a, GD1b, GT1b, and GQ1b); lane 2, standard GT1a; lane 3, standard GT1a $\alpha$ ; lane 4, reaction products without any acceptors; lane 5, reaction products from GD1a; lane 7, standard GQ1b $\alpha$ ; lane 8, reaction products without any acceptors; lane 9, reaction products from GT1b. TLC plate was developed first with solvent C and then solvent A in the same direction (panel I and II). For panel III and IV, the plate was developed by the same procedure except solvent B as the second solvent.

was found in rat liver [19] and brain [22]. It is not clear whether or not the formation of Chol-1 gangliosides and GD1a is performed by a single GalNAc  $\alpha$ 2-6 sialyltransferase. When GT1a $\alpha$  and GQ1b $\alpha$  were used as substrates, no radiolabeled ganglioside products could be detected (data not shown), suggesting that the two gangliosides are final products of ganglioside metabolism, and the GalNAc  $\alpha$ 2-6 sialyltransferase may be responsible for the termination of ganglioside synthesis.

### 3.2. Detection of Chol-1 gangliosides in normal rat liver

Since rat liver contained enzyme activity for the synthesis of Chol-1 gangliosides, we examined whether the same tissue pos-

sesses Chol-1 gangliosides by sensitive TLC-immunostaining with GGR-41. As shown in Fig. 4, the lipid fraction from rat liver gave two immunoreactive spots corresponding to GT1a $\alpha$  and GQ1b $\alpha$ . Densitometric analysis of the immunostained spots showed that the amount of GT1a $\alpha$  and GQ1b $\alpha$  were 0.75 and 1.5  $\mu$ g per g dry tissue weight, respectively. The two major immunoreactive compounds moved slightly ahead of the corresponding standard gangliosides isolated from bovine brain tissues. This must be due to the compositional differences in their ceramide moiety. Ceramides from rat liver gangliosides have been shown to contain C22:0 and C24:0 as the predominant fatty acids [23].

In conclusion, rat liver contained an GalNAc  $\alpha$ 2-6 sialyltransferase, which transfers a sialic acid to the C6 position of the penultimate GalNAc residue in the gangliotetraose chain. This enzyme is of particular importance since the action of this enzyme may terminate further sialylation of ganglioside series gangliosides.




Fig. 3. Identification of products by TLC-immunostaining with GGR-41. Radiolabeled reaction products were purified by preparative TLC. The purified reaction products were analyzed by FUJIX BAS 2000 (panel I) and immunostaining with GGR-41 (panel II). Lane 1, standard GT1a $\alpha$  and GQ1b $\alpha$ ; lane 2, GT1a $\alpha$  synthesized from GD1a; lane 3, GQ1b $\alpha$  synthesized from GT1b. The plate was developed first with solvent C and then solvent A in the same direction.

Table 2  
Effect of incubation condition on GT1a $\alpha$  and GQ1b $\alpha$  synthase

Conditions	Synthase activity (pmol/mg protein/h) <sup>a</sup>	
	GT1a $\alpha$	GQ1b $\alpha$
Complete	25.7	29.0
–Mg <sup>2+</sup>	26.1	29.3
–Mn <sup>2+</sup>	25.9	28.8
–Mg <sup>2+</sup> , Mn <sup>2+</sup>	25.6	29.2
–Triton CF-54	11.7	14.4
–Acceptor	n.d.	n.d.
–CMP-NeuAc	n.d.	n.d.
–Enzyme	n.d.	n.d.

<sup>a</sup>The measurement of sialyltransferase activity was carried out by densitometric analysis of TLC-immunostaining with GGR-41. n.d., not detected.




Fig. 4. The presence of GT1a $\alpha$  and GQ1b $\alpha$  in rat liver. GT1a $\alpha$  and GQ1b $\alpha$  in rat liver were detected by TLC-immunostaining with GGR-41. Lane 1, standard GT1a $\alpha$  (40 ng) and GQ1b $\alpha$  (25 ng) from bovine brain; lane 2, ganglioside fraction from 2 mg of dried rat brain tissue; lane 3, ganglioside fraction from 20 mg of dried rat liver tissue. TLC plate was developed first with solvent C and then solvent A in the same direction.

**Acknowledgements:** This work was supported by a Grant-in Aid for Scientific Research on Priority Area, to Y.H., No.05274106, from the Ministry of Education, Science and Culture of Japan, an NIH Grant NS 09626 to Y.-T. Li, and Fellowships of the Japan Society for the Promotion of Science for Japanese Junior Scientists to F.I.

## References

- [1] Feizi, T. (1985) *Nature* 314, 53–57.
- [2] Hannun, Y.A. and Bell, R.M. (1989) *Science* 243, 500–507.
- [3] Hakomori, S. (1990) *J. Biol. Chem.* 265, 18713–18716.
- [4] Varki, A. (1993) *Glycobiology* 3, 97–130.
- [5] Hirabayashi, Y., Nakao, T., Matsumoto, M., Obata, K. and Ando, S. (1988) *J. Chromatogr.* 445, 377–384.
- [6] Hirabayashi, Y., Hyogo, A., Nakao, T., Tsuchiya, K., Suzuki, Y., Matsumoto, M., Kon, K. and Ando, S. (1990) *J. Biol. Chem.* 265, 8144–8151.
- [7] Hidari, K.I.-P.J., Irie, F., Suzuki, M., Kon, K., Ando, S. and Hirabayashi, Y. (1993) *Biochem. J.* 296, 259–263.
- [8] Nakao, T., Kon, K., Ando, S., Miyatake, T., Yuki, N., Li, Y.-T., Furuya, S. and Hirabayashi, Y. (1993) *J. Biol. Chem.* 268, 21028–21034.
- [9] Hirabayashi, Y., Nakao, T., Irie, F., Whittaker, V.P., Kon, K. and Ando, S. (1992) *J. Biol. Chem.* 267, 12973–12978.
- [10] Ando, S., Hirabayashi, Y., Kon, K., Inagaki, F., Tate, S. and Whittaker, V.P. (1992) *J. Biochem. (Tokyo)* 111, 287–290.
- [11] Richardson, P.J., Walker, J.H., Jones, R.T. and Whittaker, V.P. (1982) *J. Neurochem.* 38, 1605–1614.
- [12] Obroccki, J. and Borroni, E. (1988) *Exp. Brain Res.* 72, 71–82.
- [13] Irie, F., Hashikawa, T., Seyama, Y. and Hirabayashi, Y. (1993) *Glycoconjugate J.* 10, 292–293.
- [14] Chou, M.-Y., Li, S.-C., Kiso, M., Hasegawa, A. and Li, Y.-T. (1994) *J. Biol. Chem.*, in press.
- [15] Li, Y.-T., Nakagawa, H., Ross, S.A., Hansson, G.C. and Li, S.-C. (1990) *J. Biol. Chem.* 265, 21629–21633.
- [16] Higashi, H., Ikuta, K., Ueda, S., Kato, S., Hirabayashi, Y., Matsuoto, M. and Naiki, M. (1984) *J. Biochem. (Tokyo)* 95, 785–794.
- [17] Kusunoki, S., Chiba, A., Hirabayashi, Y., Irie, F., Kotani, M., Kawashima, I., Tai, T. and Nagai, Y. (1993) *Brain Res.* 623, 83–88.
- [18] Sandberg, P.-O., Marzella, L. and Glumann, H. (1980) *Exp. Cell Res.* 130, 393–400.
- [19] Hidari, K.I.-P.J., Sanai, Y., Kawashima, I., Tai, T., Inagaki, F. and Nagai, Y. (1994) *Eur. J. Biochem.* 221, 603–609.
- [20] Suzuki, Y., Nishi, H., Hidari, K., Hirabayashi, Y., Matsumoto, M., Kobayashi, T., Watarai, S., Yasuda, T., Nakayama, J., Maeda, H., Katsuyama, T., Kanai, M., Kiso, M. and Hasegawa, A. (1991) *J. Biochem. (Tokyo)* 109, 354–360.
- [21] Iber, H. and Sandhoff, K. (1989) *FEBS Lett.* 254, 124–128.
- [22] Seyfried, T.N., Novikov, A.M., Irvine, R.A. and Brigande, J.V. (1994) *J. Lipid Res.* 35, 993–1001.
- [23] Dyatolovitskaya, E.V., Novikov, A.M., Gorkova, N.P. and Bergelson, L.D. (1976) *Eur. J. Biochem.* 63, 357–364.
- [24] Svennerholm, L. (1963) *J. Neurochem.* 10, 613–623.